News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oxford Expression Technologies Ltd (OET) Strengthens Commercial Team with Appointment of Business Development Manager and Sales Manager, and Completes Second Round of Funding



12/3/2008 10:08:14 AM

Oxford Expression Technologies Ltd (OET), a leading provider of baculovirus-based protein expression products and services, has announced the appointments of Mr Tim Bernard as Business Development Manager and Dr Richard Broadhead as Sales Manager. OET has also announced the completion of a second round of funding. Investors in this round include existing shareholders and Tim Bernard.

Mr Bernard has 24 years’ experience in international executive level leadership within the life science sector, having managed teams across a global operation. He was also a key contributor in the set up, expansion and eventual sale of a life science business, growing the operation from £300k turnover to its final value of £20m. In addition, Mr Bernard led the integration process following acquisition.

Dr Broadhead brings significant global, sales and marketing experience to the company, having previous experience in the field with Invitrogen and Flowgen. He also has extensive technical experience in the field of proteomics and protein expression.

“The appointments of Tim and Richard add to the already strong team at OET, and both will be ideally placed to drive the commercial development of the business,” says James Bernard, acting CEO of OET. “The completion of this investment round, along with the continued success of our products, puts OET in an exceptional position moving into 2009,” he adds.

About Oxford Expression Technologies

Oxford Expression Technologies (OET) is a biotechnology company and centre of excellence for baculovirus protein expression. Specialising in the use of the baculovirus expression vector system, a eukaryotic expression system that can express a large variety of recombinant proteins, OET provides protein expression products, services and consultancy to many global pharmaceutical companies. OET’s proprietary flashBAC technology enables large amounts of a given protein to be produced in culture. The Company’s internationally renowned expertise and products enable proteins to be produced faster, more easily and cost-effectively using automated and high-throughput methods compared with other baculovirus systems. This contributes to the development of new drugs and research targeted towards understanding how proteins work in health and disease.

The company was founded in 2007 from a collaboration between Oxford Brookes University and the Natural Environment Research Council to provide researchers with custom proteins for research purposes. For further details about the Company’s services and products, please visit http://www.oetltd.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES